Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small …
T Kishikawa, T Kasai, M Okada, I Nakachi… - Thoracic …, 2020 - Wiley Online Library
Background Osimertinib is recommended for T790M mutation‐positive advanced non‐small
cell lung cancer (NSCLC) resistant to first‐and second‐generation epidermal growth factor …
cell lung cancer (NSCLC) resistant to first‐and second‐generation epidermal growth factor …
Impact of T790M mutation status on Later-Line osimertinib treatment in non-small cell lung cancer patients
YJ Tang, JWC Chang, CF Chang, CY Huang, CT Yang… - Cancers, 2022 - mdpi.com
Simple Summary Osimertinib is a third-generation epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in …
kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in …
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial
Osimertinib is a molecularly targeted agent used to treat non-small cell lung cancer
(NSCLC) patients with an epidermal growth factor receptor (EGFR) T790M mutation …
(NSCLC) patients with an epidermal growth factor receptor (EGFR) T790M mutation …
[HTML][HTML] Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to …
Y Kato, Y Hosomi, K Watanabe, M Yomota… - Journal of Thoracic …, 2019 - ncbi.nlm.nih.gov
Background Osimertinib exhibits good efficacy in patients with T790M-positive non-small
cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor …
cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor …
The efficacy of a reduced dose (40mg) of osimertinib with T790M-positive advanced non-small-cell lung cancer
S Sonobe, Y Taniguchi, N Saijo, Y Naoki… - Annals of …, 2017 - annalsofoncology.org
Background: The third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib is now
the standard therapy for patients with T790M-positive advanced non-small-cell lung cancer …
the standard therapy for patients with T790M-positive advanced non-small-cell lung cancer …
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first-and second-generation EGFR-TKI …
Y Tsubata, K Watanabe, R Saito, A Nakamura… - International Journal of …, 2022 - Springer
Background Osimertinib is effective in patients with T790M mutation-positive advanced non-
small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) …
small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) …
Real-world data on osimertinib in Chinese patients with pretreated, EGFR T790M mutation positive, advanced non-small cell lung cancer: a retrospective study
D Peng, D Shan, C Dai, J Li, Z Wang… - Cancer Management …, 2021 - Taylor & Francis
Purpose As a third-generation EGFR TKI has been taken orally, Osimertinib effectively
inhibits mutant EGFR, including T790M EGFR resistance mutations. Here, we examined real …
inhibits mutant EGFR, including T790M EGFR resistance mutations. Here, we examined real …
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
JB Auliac, M Pérol, D Planchard, I Monnet, M Wislez… - Lung Cancer, 2019 - Elsevier
Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell
lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in …
lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in …
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
M Santarpia, A Liguori, N Karachaliou… - Lung Cancer: Targets …, 2017 - Taylor & Francis
The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
Osimertinib: a review in T790M-positive advanced non-small cell lung cancer
YN Lamb, LJ Scott - Targeted oncology, 2017 - Springer
Osimertinib (Tagrisso™) is an oral, CNS-active, third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations …
receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations …
相关搜索
- lung cancer egfr tki
- status patients egfr tki
- osimertinib for patients egfr t790m
- performance status egfr t790m
- lung cancer osimertinib in the treatment
- lung cancer status patients
- lung cancer place in therapy
- lung cancer reduced dose
- lung cancer egfr t790m
- lung cancer osimertinib for patients
- lung cancer performance status